Cargando…
Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan
This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426944/ https://www.ncbi.nlm.nih.gov/pubmed/36040882 http://dx.doi.org/10.1371/journal.pone.0273712 |
_version_ | 1784778792669020160 |
---|---|
author | Ishizaki, Azumi Bi, Xiuqiong Nguyen, Quynh Thi Maeno, Tomomi Hara, Akinori Nakamura, Hiroyuki Kuramoto, Sanae Nishi, Koichi Ooe, Hiroyasu Ichimura, Hiroshi |
author_facet | Ishizaki, Azumi Bi, Xiuqiong Nguyen, Quynh Thi Maeno, Tomomi Hara, Akinori Nakamura, Hiroyuki Kuramoto, Sanae Nishi, Koichi Ooe, Hiroyasu Ichimura, Hiroshi |
author_sort | Ishizaki, Azumi |
collection | PubMed |
description | This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infected with SARS-CoV-2 in April 2020 for 12 months (12M). Patients were tested for NAbs and for antibodies against the SARS-CoV-2 nucleocapsid (anti-NC-Ab) and antibodies against the spike receptor-binding domain (anti-RBD-Ab). Tests were performed at 2M, 6M, and 12M after the primary infection (api) with commercially available test kits. In 90.9% (30/33) of patients, NAbs persisted for 12M api, though the median titers significantly declined from 78.7% (interquartile range [IQR]: 73.0–85.0%) at 2M, to 59.8% (IQR: 51.2–77.9) at 6M (P = 0.008), and to 56.2% (IQR: 39.6–74.4) at 12M (P<0.001). An exponential decay model showed that the NAb level reached undetectable concentrations at 35.5 months api (95% confidence interval: 26.5–48.0 months). Additionally, NAb titers were significantly related to anti-RBD-Ab titers (rho = 0.736, P<0.001), but not to anti-NC-Ab titers. In most patients convalescing from COVID-19, NAbs persisted for 12M api. This result suggested that patients need a booster vaccination within one year api, even though NAbs could be detected for over two years api. Anti-RBD-Ab titers could be used as a surrogate marker for predicting residual NAb levels. |
format | Online Article Text |
id | pubmed-9426944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94269442022-08-31 Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan Ishizaki, Azumi Bi, Xiuqiong Nguyen, Quynh Thi Maeno, Tomomi Hara, Akinori Nakamura, Hiroyuki Kuramoto, Sanae Nishi, Koichi Ooe, Hiroyasu Ichimura, Hiroshi PLoS One Research Article This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infected with SARS-CoV-2 in April 2020 for 12 months (12M). Patients were tested for NAbs and for antibodies against the SARS-CoV-2 nucleocapsid (anti-NC-Ab) and antibodies against the spike receptor-binding domain (anti-RBD-Ab). Tests were performed at 2M, 6M, and 12M after the primary infection (api) with commercially available test kits. In 90.9% (30/33) of patients, NAbs persisted for 12M api, though the median titers significantly declined from 78.7% (interquartile range [IQR]: 73.0–85.0%) at 2M, to 59.8% (IQR: 51.2–77.9) at 6M (P = 0.008), and to 56.2% (IQR: 39.6–74.4) at 12M (P<0.001). An exponential decay model showed that the NAb level reached undetectable concentrations at 35.5 months api (95% confidence interval: 26.5–48.0 months). Additionally, NAb titers were significantly related to anti-RBD-Ab titers (rho = 0.736, P<0.001), but not to anti-NC-Ab titers. In most patients convalescing from COVID-19, NAbs persisted for 12M api. This result suggested that patients need a booster vaccination within one year api, even though NAbs could be detected for over two years api. Anti-RBD-Ab titers could be used as a surrogate marker for predicting residual NAb levels. Public Library of Science 2022-08-30 /pmc/articles/PMC9426944/ /pubmed/36040882 http://dx.doi.org/10.1371/journal.pone.0273712 Text en © 2022 Ishizaki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ishizaki, Azumi Bi, Xiuqiong Nguyen, Quynh Thi Maeno, Tomomi Hara, Akinori Nakamura, Hiroyuki Kuramoto, Sanae Nishi, Koichi Ooe, Hiroyasu Ichimura, Hiroshi Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan |
title | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan |
title_full | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan |
title_fullStr | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan |
title_full_unstemmed | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan |
title_short | Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan |
title_sort | neutralizing-antibody response to sars-cov-2 for 12 months after the covid-19 workplace outbreaks in japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426944/ https://www.ncbi.nlm.nih.gov/pubmed/36040882 http://dx.doi.org/10.1371/journal.pone.0273712 |
work_keys_str_mv | AT ishizakiazumi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT bixiuqiong neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT nguyenquynhthi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT maenotomomi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT haraakinori neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT nakamurahiroyuki neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT kuramotosanae neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT nishikoichi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT ooehiroyasu neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan AT ichimurahiroshi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan |